


## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

### Listing of Claims

1. (Currently amended) A compound of Formula I



wherein

R is H,

R<sup>1a</sup> is independently selected from

- 1) H,
- 2) C<sub>1</sub>-C<sub>6</sub> alkyl, and
- 3) OR<sup>4</sup>;

R<sup>1b</sup> is independently selected from

- 1) H, and
- 2) C<sub>1</sub>-C<sub>6</sub> alkyl;

X is selected from

- 1) a bond,
- 2) C(O), and
- 3) O,

R<sup>1</sup> is independently selected from

- 1) H,
- 2) halo,
- 3) OR<sup>4</sup>,
- 4) NO<sub>2</sub>,
- 5) C<sub>1</sub>-C<sub>10</sub> alkyl,
- 6) -C(O)R<sup>4</sup>,
- 7) C(O)OR<sup>4</sup>,

- 8)  $\text{C}(\text{O})\text{N}(\text{R}^4)_2$ ,
- 9)  $\text{N}(\text{R}^4)_2$ ;

$\text{V}$  is selected from aryl-phenyl, benzofuran, benzodioxo and oxazolo;

$\text{R}^2$  is independently selected from

- 1) H,
- 2)  $\text{C}_1\text{-C}_{10}$  alkyl,
- 3)  $-(\text{CR}^{1b})_t\text{OR}^4$ ,
- 4) Halo,
- 5) CN,
- 6)  $\text{NO}_2$ ,
- 7)  $\text{CF}_3$ ,
- 8)  $-(\text{CR}^{1b})_t\text{N}(\text{R}^4)_2$ ,
- 9)  $-\text{C}(\text{O})\text{OR}^4$ ,
- 10)  $-\text{C}(\text{O})\text{R}^4$ ,
- 11)  $-(\text{CR}^{1b})_t\text{NR}^4(\text{CR}^{1b})_t\text{R}^5$ ,
- 12)  $-(\text{CR}^{1b})_t\text{S}(\text{O})_m\text{NR}^4$ ,
- 13)  $-\text{C}(\text{O})\text{OR}^4\text{R}^5$ ,
- 14)  $-\text{NR}^4\text{C}(\text{O})\text{R}^4$ ,

$\text{R}^4$  is independently selected from

- 1) H,
- 2)  $\text{C}_1\text{-C}_{10}$  alkyl,
- 3)  $\text{C}_3\text{-C}_{10}$  cycloalkyl,
- 4) aryl,
- 5) heterocycle, and
- 6)  $\text{CF}_3$ ;

$\text{R}^5$  is independently selected from

- 1) aryl, and
- 2) heterocycle;

$\text{m}$  is independently 0, 1 or 2;

$\text{n}$  is 0 to 4;

$\text{p}$  is 0 to 4;

$\text{q}$  is 1 to 4;

$\text{s}$  is 0 to 16; and

t is independently 0 to 6;

or a pharmaceutically acceptable salt or stereoisomer thereof.

2. (Previously presented) The compound according to Claim 1 wherein R, R<sup>1b</sup>, R<sup>4</sup>, R<sup>5</sup>, V and variables m, n, p, q and t are as defined in Claim 1 and

R<sup>1a</sup> is independently selected from

- 1) H, and
- 2) C<sub>1</sub>-C<sub>6</sub> alkyl;

X is selected from

- 1) a bond, and
- 2) C(O);

R<sup>1</sup> is independently selected from

- 1) H,
- 2) halo,
- 3) OR<sup>4</sup>,
- 4) N(R<sup>4</sup>)<sub>2</sub>,
- 5) NO<sub>2</sub>, and

R<sup>2</sup> is independently selected from

- 1) H,
- 2) C<sub>1</sub>-C<sub>10</sub> alkyl, and
- 3) Halo,

s is 0 to 6;

or a pharmaceutically acceptable salt or stereoisomer thereof.

3. (Currently amended) The compound according to Claim 1 or 2 wherein R, R<sup>1b</sup>, X, R<sup>1</sup>, R<sup>2</sup>, R<sup>4</sup>, R<sup>5</sup> and variables m and t are as defined above in Claim 2 and:

R<sup>1a</sup> is independently selected from

- 1) H, and
- 2) C<sub>1</sub>-C<sub>6</sub> alkyl;

V is phenyl;

n is 0 or 1;  
p is 0 to 3;  
q is 1 to 3;

or a pharmaceutically acceptable salt or stereoisomer thereof.

4. (Original) A compound that is:

(6*R*,9*S*,11*R*)-11-phenyl-5,6,7,8,9,10-hexahydro-6,9-(epiminomethano)benzo [*a*][8]annulene;

(6*R*,9*R*,11*S*)-11-phenyl-5,6,7,8,9,10-hexahydro-6,9-(epiminomethano)benzo [*a*][8]annulene;

(6*S*,9*R*,11*R*)-11-phenyl-5,6,7,8,9,10-hexahydro-6,9-(epiminomethano)benzo [*a*][8]annulene;

(6*S*,9*R*,11*S*)-11-phenyl-5,6,7,8,9,10-hexahydro-6,9-(epiminomethano)benzo [*a*][8]annulene;

(6*S*,9*R*,11*R*)-11-benzyl-5,6,7,8,9,10-hexahydro-6,9-(epiminomethano)benzo [*a*][8]annulene;

(6*S*,9*R*,11*R*)-11-benzyl-5,6,7,8,9,10-hexahydro-6,9-(epiminomethano)benzo [*a*][8]annulene;

(6*R*,9*S*,11*S*)-11-benzyl-5,6,7,8,9,10-hexahydro-6,9-(epiminomethano)benzo [*a*][8]annulene;

(6*R*,9*S*,11*R*)-11-benzyl-5,6,7,8,9,10-hexahydro-6,9-(epiminomethano)benzo [*a*][8]annulene;

(6*S*,9*R*,11*S*)-11-(3-bromobenzyl)-5,6,7,8,9,10-hexahydro-6,9-(epiminomethano)benzo[*a*][8]annulene;

(6*S*,9*R*,11*R*)-11-(3-bromobenzyl)-5,6,7,8,9,10-hexahydro-6,9-(epiminomethano)benzo[*a*][8]annulene;

(6*R*,9*S*,11*S*)-11-(3-bromobenzyl)-5,6,7,8,9,10-hexahydro-6,9-(epiminomethano)benzo[*a*][8]annulene;

(6*R*,9*S*,11*R*)-11-(3-bromobenzyl)-5,6,7,8,9,10-hexahydro-6,9-(epiminomethano)

benzo[*a*][8]annulene;

(6*S*,9*R*,11*S*)-11-(1,3-benzodioxol-5-ylmethyl)-5,6,7,8,9,10-hexahydro-6,9-(epiminomethano)benzo[*a*][8]annulene;

(6*S*,9*R*,11*R*)-11-(1,3-benzodioxol-5-ylmethyl)-5,6,7,8,9,10-hexahydro-6,9-(epiminomethano)benzo[*a*][8]annulene;

(6*R*,9*S*,11*S*)-11-(1,3-benzodioxol-5-ylmethyl)-5,6,7,8,9,10-hexahydro-6,9-(epiminomethano)benzo[*a*][8]annulene;

(6*R*,9*S*,11*R*)-11-(1,3-benzodioxol-5-ylmethyl)-5,6,7,8,9,10-hexahydro-6,9-(epiminomethano)benzo[*a*][8]annulene;

(6*S*,9*R*,11*S*)-11-(3-bromobenzyl)-5,6,7,8,9,10-hexahydro-6,9-(epiminomethano)benzo[*a*][8]annulen-4-amine;

(6*S*,9*R*,11*R*)-11-(3-bromobenzyl)-5,6,7,8,9,10-hexahydro-6,9-(epiminomethano)benzo[*a*][8]annulen-4-amine;

(6*R*,9*S*,11*S*)-11-(3-bromobenzyl)-5,6,7,8,9,10-hexahydro-6,9-(epiminomethano)benzo[*a*][8]annulen-4-amine;

(6*R*,9*S*,11*R*)-11-(3-bromobenzyl)-5,6,7,8,9,10-hexahydro-6,9-(epiminomethano)benzo[*a*][8]annulen-4-amine;

(6*S*,9*R*,11*S*)-11-(3-bromobenzyl)-5,6,7,8,9,10-hexahydro-6,9-(epiminomethano)benzo[*a*][8]annulen-1-amine;

(6*S*,9*R*,11*R*)-11-(3-bromobenzyl)-5,6,7,8,9,10-hexahydro-6,9-(epiminomethano)benzo[*a*][8]annulen-1-amine;

(6*R*,9*S*,11*S*)-11-(3-bromobenzyl)-5,6,7,8,9,10-hexahydro-6,9-(epiminomethano)benzo[*a*][8]annulen-1-amine;

(6*R*,9*S*,11*R*)-11-(3-bromobenzyl)-5,6,7,8,9,10-hexahydro-6,9-(epiminomethano)benzo[*a*][8]annulen-1-amine;

(6*S*,9*R*,11*S*)-11-(1-benzofuran-2-ylmethyl)-5,6,7,8,9,10-hexahydro-6,9-(epiminomethano)benzo[*a*][8]annulene;

(6*S*,9*R*,11*R*)-11-(1-benzofuran-2-ylmethyl)-5,6,7,8,9,10-hexahydro-6,9-(epiminomethano)benzo[*a*][8]annulene;

(6*R*,9*S*,11*S*)-11-(1-benzofuran-2-ylmethyl)-5,6,7,8,9,10-hexahydro-6,9-(epiminomethano)benzo[*a*][8]annulene;

(6*R*,9*S*,11*R*)-11-(1-benzofuran-2-ylmethyl)-5,6,7,8,9,10-hexahydro-6,9-(epiminomethano)benzo[*a*][8]annulene;

(6*S*,9*R*,11*S*)-11-(1,3-oxazol-2-ylmethyl)-5,6,7,8,9,10-hexahydro-6,9-(epiminomethano)benzo[*a*][8]annulene;

(6*S*,9*R*,11*R*)-11-(1,3-oxazol-2-ylmethyl)-5,6,7,8,9,10-hexahydro-6,9-(epiminomethano)benzo[*a*][8]annulene;

(6*R*,9*S*,11*S*)-11-(1,3-oxazol-2-ylmethyl)-5,6,7,8,9,10-hexahydro-6,9-(epiminomethano)benzo[*a*][8]annulene;

(6*R*,9*S*,11*R*)-11-(1,3-oxazol-2-ylmethyl)-5,6,7,8,9,10-hexahydro-6,9-(epiminomethano)benzo[*a*][8]annulene;

(6*S*,9*R*,11*S*)-11-isopentyl-5,6,7,8,9,10-hexahydro-6,9-(epiminomethano)benzo[*a*][8]annulene;

(6*S*,9*R*,11*R*)-11-isopentyl-5,6,7,8,9,10-hexahydro-6,9-(epiminomethano)benzo[*a*][8]annulene;

(6*R*,9*S*,11*S*)-11-isopentyl-5,6,7,8,9,10-hexahydro-6,9-(epiminomethano)benzo[*a*][8]annulene;

(6*R*,9*S*,11*R*)-11-isopentyl-5,6,7,8,9,10-hexahydro-6,9-(epiminomethano)benzo[*a*][8]annulene;

or a pharmaceutically acceptable salt or stereoisomer thereof.

5. (Original) A compound according to Claim 4 that is:

(6*R*,9*S*,11*R*)-11-phenyl-5,6,7,8,9,10-hexahydro-6,9-(epiminomethano)benzo[*a*][8]annulene;

(6*R*,9*R*,11*S*)-11-phenyl-5,6,7,8,9,10-hexahydro-6,9-(epiminomethano)benzo [a][8]annulene;

(6*S*,9*R*,11*R*)-11-phenyl-5,6,7,8,9,10-hexahydro-6,9-(epiminomethano)benzo [a][8]annulene;

(6*S*,9*R*,11*S*)-11-phenyl-5,6,7,8,9,10-hexahydro-6,9-(epiminomethano)benzo [a][8]annulene;

or a pharmaceutically acceptable salt or stereoisomer thereof.

6-21. (Canceled)

22. (Currently amended) A pharmaceutical composition which is comprised of a compound in accordance with Claim 1 and a pharmaceutically acceptable carrier.